Ipsen S.A. (EPA:IPN)
162.70
-6.10 (-3.61%)
Jul 10, 2026, 5:35 PM CET
Ipsen Employees
Ipsen had 5,535 employees as of December 31, 2025. The number of employees increased by 177 or 3.30% compared to the previous year.
Employees
5,535
Change (1Y)
177
Growth (1Y)
3.30%
Revenue / Employee
€709,883
Profits / Employee
€80,126
Market Cap
13.36B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 5,535 | 177 | 3.30% | 5,535 | 0 |
| Dec 31, 2024 | 5,358 | 33 | 0.62% | 5,358 | 0 |
| Dec 31, 2023 | 5,325 | 253 | 4.99% | 5,325 | 0 |
| Dec 31, 2022 | 5,072 | -672 | -11.70% | 5,072 | 0 |
| Dec 31, 2021 | 5,744 | 41 | 0.72% | 5,744 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 155,975 |
| emeis Société anonyme | 84,586 |
| Sanofi | 74,846 |
| Clariane SE | 70,685 |
| Eurofins Scientific SE | 65,694 |
| Ramsay Générale de Santé | 40,000 |
| bioMérieux | 15,226 |
| Sartorius Stedim Biotech | 10,456 |
Ipsen News
- 1 day ago - Ipsen Reports Reduced Migraine Days With Dysport In Phase 3 BEOND Topline Data - Nasdaq
- 7 days ago - Drugmaker Ipsen Sees More Deals Coming to Continue Buying Spree - WSJ
- 8 days ago - Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal - Nasdaq
- 9 days ago - Ipsen Acquires Memo Therapeutics for Over â¬700 Million - GuruFocus
- 9 days ago - Ipsen To Acquire Memo Therapeutics For Over 700 Mln Euros, Expanding Rare Disease Portfolio - Nasdaq
- 9 days ago - Ipsen (IPSEY) to Acquire Memo Therapeutics for Over â¬700M - GuruFocus
- 9 days ago - Ipsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Million - WSJ
- 9 days ago - Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio - GlobeNewsWire